Last reviewed · How we verify

Zenapax®, CellCept® and prednisolone

University of Oslo School of Pharmacy · FDA-approved active Small molecule

Zenapax®, CellCept® and prednisolone is a Immunosuppressive combination therapy Small molecule drug developed by University of Oslo School of Pharmacy. It is currently FDA-approved for Prevention of acute organ rejection in renal transplant recipients, Prevention of acute organ rejection in other solid organ transplants.

This combination suppresses the immune system to prevent organ rejection after transplantation by blocking T-cell activation and proliferation while reducing corticosteroid-induced inflammation.

This combination suppresses the immune system to prevent organ rejection after transplantation by blocking T-cell activation and proliferation while reducing corticosteroid-induced inflammation. Used for Prevention of acute organ rejection in renal transplant recipients, Prevention of acute organ rejection in other solid organ transplants.

At a glance

Generic nameZenapax®, CellCept® and prednisolone
SponsorUniversity of Oslo School of Pharmacy
Drug classImmunosuppressive combination therapy
TargetIL-2 receptor (daclizumab); inosine monophosphate dehydrogenase (mycophenolate mofetil); glucocorticoid receptor (prednisolone)
ModalitySmall molecule
Therapeutic areaImmunology / Transplantation
PhaseFDA-approved

Mechanism of action

Zenapax (daclizumab) is a monoclonal antibody that blocks the IL-2 receptor on T cells, preventing their activation. CellCept (mycophenolate mofetil) inhibits inosine monophosphate dehydrogenase, selectively suppressing T and B cell proliferation. Prednisolone is a corticosteroid that broadly suppresses immune responses. Together, this triple therapy provides multi-targeted immunosuppression for transplant rejection prevention.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about Zenapax®, CellCept® and prednisolone

What is Zenapax®, CellCept® and prednisolone?

Zenapax®, CellCept® and prednisolone is a Immunosuppressive combination therapy drug developed by University of Oslo School of Pharmacy, indicated for Prevention of acute organ rejection in renal transplant recipients, Prevention of acute organ rejection in other solid organ transplants.

How does Zenapax®, CellCept® and prednisolone work?

This combination suppresses the immune system to prevent organ rejection after transplantation by blocking T-cell activation and proliferation while reducing corticosteroid-induced inflammation.

What is Zenapax®, CellCept® and prednisolone used for?

Zenapax®, CellCept® and prednisolone is indicated for Prevention of acute organ rejection in renal transplant recipients, Prevention of acute organ rejection in other solid organ transplants.

Who makes Zenapax®, CellCept® and prednisolone?

Zenapax®, CellCept® and prednisolone is developed and marketed by University of Oslo School of Pharmacy (see full University of Oslo School of Pharmacy pipeline at /company/university-of-oslo-school-of-pharmacy).

What drug class is Zenapax®, CellCept® and prednisolone in?

Zenapax®, CellCept® and prednisolone belongs to the Immunosuppressive combination therapy class. See all Immunosuppressive combination therapy drugs at /class/immunosuppressive-combination-therapy.

What development phase is Zenapax®, CellCept® and prednisolone in?

Zenapax®, CellCept® and prednisolone is FDA-approved (marketed).

What are the side effects of Zenapax®, CellCept® and prednisolone?

Common side effects of Zenapax®, CellCept® and prednisolone include Infection (bacterial, viral, fungal), Gastrointestinal disturbances (diarrhea, nausea), Leukopenia, Tremor, headache, Hyperglycemia, Hypertension.

What does Zenapax®, CellCept® and prednisolone target?

Zenapax®, CellCept® and prednisolone targets IL-2 receptor (daclizumab); inosine monophosphate dehydrogenase (mycophenolate mofetil); glucocorticoid receptor (prednisolone) and is a Immunosuppressive combination therapy.

Related